The expert meeting dedicated to the discussion of results of a local open-label multicenter observational study of the efficiency and safety of tofacitinib in patients with active rheumatoid arthritis with the inefficiency of disease-modifying antirheumatic drugs and to the elaboration of recommendations for the use for tofacitinib in the therapy of rheumatoid arthritis
Abstract
The expert meeting dedicated to the discussion of results of a local open-label multicenter observational study of the efficiency and safety of tofacitinib in patients with active rheumatoid arthritis with the inefficiency of disease-modifying antirheumatic drugs and to the elaboration of recommendations for the use for tofacitinib in the therapy of rheumatoid arthritis.
References
1. Регистрационное удостоверение лекарственного препарата для медицинского применения ЛП-002026 [Certificate of registration of the drug for medical use LP-002026].
2. Инструкция по медицинскому применению препарата Яквинус – таблетки, покрытые пленочной оболочкой, утверждена МЗ РФ 16.03.2013 г., рег. уд. ЛП 002026 от 16.03.2013 г. с изменениями от 21.04.2014 г. [Instruction for use Yakvinus medication – tablets, film-coated, approved by the Ministry of Health of the Russian Federation of 16.03.2013, reg. sp. LP 002026 from 16.03.2013, as amended on 04.21.2014].
3. Насонов ЕЛ. Новые подходы к фармакотерапии ревматоидного артрита: тофацитиниб. Научно-практическая ревматология. 2014;52(2):209-21 [Nasonov EL. New approaches to pharmacotherapy of rheumatoid arthritis: tofacitinib. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(2):209-221. (In Russ.)]. doi: 10.14412/1995- 4484-2014-209-221
4. Каратеев ДЕ. Новое направление в патогенетической терапии ревматоидного артрита: первый ингибитор Янускиназ тофацитиниб. Современная ревматология. 2014;8(1):39-44 [Karateev DE. A new trend in pathogenetic treatment of rheumatoid arthritis: tofacitinib, the first inhibitor of Janus kinase. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2014;8(1):39-44 (In Russ.)]. doi: 10.14412/1996-7012-2014-1-39-44
5. Fleischman R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367;495-507. doi: 10.1056/NEJMoa1109071
6. Burmister G, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451-60. doi: 10.1016/S0140-6736(12)61424-X
7. Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus Methotrexate in rheumatoid arthritis. N Engl J Med. 2014 Jun 19;370(25):2377-86. doi: 10.1056/NEJMoa1310476.
8. Kawalec P, Mikrut A, Wisniewska N, Pilc A. The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2013 Oct;32(10):1415-24. doi: 10.1007/s10067-013- 2329-9. Epub 2013 Jul 23.
9. Salgado E, Maneiro JR, Carmona L, Gomez-Reino JJ. Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis. 2014 May;73(5):871-82. doi: 10.1136/annrheumdis-2012-203116. Epub 2013 Apr 18.
10. Cohen S, Radominski SC, Gomez-Reino JJ, et al. Analysis of infections and all-cause mortality in phase ii, phase iii, and longterm externtion studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheum. 2014;66(11):2924-37. doi: 10.1002/art.38779
Review
For citations:
The expert meeting dedicated to the discussion of results of a local open-label multicenter observational study of the efficiency and safety of tofacitinib in patients with active rheumatoid arthritis with the inefficiency of disease-modifying antirheumatic drugs and to the elaboration of recommendations for the use for tofacitinib in the therapy of rheumatoid arthritis. Rheumatology Science and Practice. 2016;54(4):485-486. (In Russ.)
Views:
380
Email this article 